News
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.
The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback